Imugene Ltd - Company Profile
Powered by 
All the data and insights you need on Imugene Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Imugene Ltd Strategy Report
- Understand Imugene Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Imugene Ltd (Imugene) develops immunotherapies that activates the immune system of cancer patients to identify and eradicate tumors. The company operates through one reportable segment, including the research, development, and commercialization of oncolytic immunotherapies.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D team focuses on oncolytic immunotherapies. The company develops pipeline products based on the proprietary mimotope technology platform. It includes B-cell immunotherapies for immunogenic protein with a B-cell epitope that induces the body to produce antibodies against the normal self-proteins such as HER2 or PD-1, onCARlytics for tumors and CF33 Oncolytic Virus for chimeric vaccinia (pox) virus. The R&D expenses stood at AUD30.9 million in FY2023, reflecting a decline of 15.7% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer